

Saturday November 7, 2020

Virtual Meeting via OHSU Webex

10 AM EST (7 AM PST) – Opening Remarks (Nicole Fett)

***** Please note below times are all in EST**

*** = Co-Senior Authors**

= Co-First Authors

Oral Presentations – Sclerotic Skin Disease

Chair: Rambí Cardones, MD

Presenters have 7 minutes for presentation, 3 minutes for Q+A

10:05 AM

PILOT STUDY EVALUATING THE EFFICACY OF A TOPICAL PDE- INHIBITOR FOR MORPHEA

Amy J. Petty, Drew A. Emge, Sarah K. Blanchard, M. Angelica Selim, Adela R. Cardones

10:15 AM

NEUROLOGIC MANIFESTATIONS OF MORPHEA: A CROSS SECTIONAL STUDY OF THE MORPHEA AND ADULTS AND CHILDREN (MAC) COHORT

Laila F Abbas, BA; Adrienne Joseph, BS; Jane Zhu, BS; Heidi T Jacobe MD, MSCS

10:25 AM

CHARACTERIZING MORPHEA SUBSETS USING A MULTI-CENTER, PROSPECTIVE, CROSS-SECTIONAL ANALYSIS

Jane L Zhu, BA, Smriti Prasad, MD, MPH, Kaila Schollaert-Fitch, BS, Robert Haley, MD, Kathryn S. Torok, MD, Heidi T. Jacobe, MD, MSCS

10:35 AM

GEOGRAPHIC DISTRIBUTION AND ENVIRONMENTAL TRIGGERS OF SYSTEMIC SCLEROSIS AND EOSINOPHILIC FASCIITIS IN MASSACHUSETTS

Bina Kassamali, Anastasiya Muntyanu, Elena Netchiporouk, Ruth Ann Vleugels*, Avery LaChance*

Short Talks – Presenters have 2 minutes for presentation

10:45 AM

RECURRENCE OF FACIAL MORPHEA POST-FAT TRANSFER: A NEED FOR CAUTION

Laila F Abbas, Christian Carr, Adrienne K Joseph, Heidi T Jacobe

10:47 AM

JUVENILE LINEAR SCLERODERMA WITH FACIAL NEUROPATHY

Leigh A. Stubbs, Marietta De Guzman

10:49 AM

A MULTI-INSTITUTIONAL STUDY EXAMINING THE EFFICACY OF AND CHALLENGES IN ACQUIRING INSURANCE APPROVAL FOR BOTULINUM TOXIN INJECTIONS FOR SYSTEMIC SCLEROSIS-ASSOCIATED RAYNAUD'S PHENOMENON

Sheena Desai[#], Bina Kassamali[#], Omid Zahedi Niaki, Erin Penn, Camila Villa-Ruiz, Gabriela Cobos, Joseph Merola, Avery Lachance*, Ruth Ann Vleugels*

11:00 am Keynote Speaker Dr. Chester Oddis:

**The Assessment and Management of Myositis-Associated Interstitial Lung Disease
Professor of Medicine University of Pittsburgh, Director of Myositis Center**

Noon – 12:30 Break

12:30 Dr. Matilda Nicholas – Introducing Virtual Grand Rounds

1 PM – Keynote speaker Dr. Jinoos Yazdany:

**Managing immunomodulating Therapies and Immunocompromised Patients during the
COVID-19 Pandemic**

Chief of the Division of Rheumatology at SFGH and Professor of Medicine UCSF

Presentations – Miscellaneous/Clinical Cases

Chair: Chris Richardson, MD, PhD

Presenters have 7 minutes for presentation and 3 minutes for Q+A

2:00 PM

**LOCAL HYALURONIDASE INJECTIONS AS TREATMENT FOR ORAL MICROSTOMIA
CAUSED BY SYSTEMIC SCLEROSIS**

Michelle S Min, Lisa N. Guo, Daniel R Mazori, Gabriela A Cobos, Joseph F Merola, Ruth Ann
Vleugels, Avery LaChance

2:10 PM

SEVERE MULTICENTRIC RETICULOHISTIOCYTOSIS TREATED WITH UPADACITINIB

Omid Zahedi Niaki, Erin Penn, Deborah A Scott, Gabriela Cobos, Michael E. Weinblatt*, Ruth Ann
Vleugels*

2:20 PM

**REMISSION OF DERMATOMYOSITIS FOLLOWING ALLOGENEIC HEMATOPOETIC
STEM CELL TRANSPLANT FOR CONCURRENT MYELODYSPLASTIC SYNDROME**

Fatima Bawany, Irina Lerman, Bushra Tbakhi, Jason H. Mendler, Omar S. Aljitawi, John M. Bennett,
and Christopher T. Richardson

2:30 PM

**ERYTHEMA ELEVATUM DIUTINUM: A CASE SERIES WITH EMPHASIS ON CLINICAL
PRESENTATION AND TREATMENT RESPONSE**

Camila Villa-Ruiz, MPH#, Bridget Erin Shields, MD#; Lauren K. Rangel, Mina Bakhtiar; Misha
Rosenbach, MD*, Alisa Femia, MD*, Ruth Ann Vleugels, MD, MPH*

Short Talks Clinical Cases— Presenters have 2 minutes for presentation

2:40 PM

KOILONYCHIA SECONDARY TO RAYNAUD'S PHENOMENON: A RARE CO-OCCURRENCE

Sepideh Ashrafzadeh, Sotonye Imadojemu

2:42 PM

COEXISTENT HYPOCOMPLEMENTEMIC URTICARIAL VASCULITIS AND BOWEL-ASSOCIATED DERMATOSIS-ARTHRITIS SYNDROME: TWO NEUTROPHILIC DERMATOSES WITH SIMILAR CLINICAL PRESENTATION

Brett Cutler BS, Teri M. Greiling MD, PhD

2:44 PM

AN ATYPICAL CLINICAL PRESENTATION OF DERMATITIS HERPETIFORMIS

Dustin Taylor, Carli Whittington, Deborah Cook, Keith Morley

2:46 PM

SUBCUTANEOUS SARCOIDOSIS WITH REACTIVATION OF DORMANT SCARS

Lucy Xu, BA, Ellen B. Franciosi, BA, Mehdi Rashighi, MD

2:48 PM

CUTIS LAXA PHENOTYPE RESULTING FROM GAMMA-GLUTAMYL CARBOXYLASE MUTATION

Zachary Holcomb, MD; Camila Villa-Ruiz, MPH; Omid Zahedi Niaki, MD; Lihi Atzmony Maoz, MD; Anna Cristina Garza-Mayers, MD, PhD; Keith Choate, MD, PhD; Avery LaChance, MD, MPH

2:50 PM

CLINICAL SYMPTOMS AND A PATHOLOGICAL COMPARISON OF LYMPHOCYTIC THROMBOPHILIC ARTERITIS, CUTANEOUS POLYARTERITIS NODOSA AND POLYARTERITIS NODOSA

Mariko Ogawa-Momohara, Yoshinao Muro, Masashi Akiyama

3 – 3:30 BREAK

Oral Presentations - Dermatomyositis

Chair: Ben Chong, MD

Presenters have 7 minutes for presentation and 3 minutes for questions

3:30 PM

TYPE I AND II INTERFERON SIGNALING DIFFERENTIALLY ASSOCIATED WITH HISTOPATHOLOGIC FINDINGS IN DERMATOMYOSITIS SKIN

Tiffany Wu, Mika Tabata, Luqman Mushila Hodgkinson, Sung Kyung Cho, Karen Page, Christine Huard, Janet Buhlmann, Kavita Sarin, David Fiorentino

3:40 PM

IDENTIFICATION OF IL31+IL4+ mDCs IN DERMATOMYOSITIS AS POSSIBLE CONTRIBUTORS TO ITCH

Jay Patel, Spandana Maddukuri, Thomas Vazquez, Yubin Li, Christina Bax, Victoria Werth

3:50 PM

HERBAL SUPPLEMENT SPIRULINA STIMULATES INFLAMMATORY CYTOKINE PRODUCTION VIA TOLL LIKE RECEPTOR- RECEPTOR ACTIVATION IN-VITRO IN DERMATOMYOSITIS PATIENTS

Christina E. Bax, Yubin Li, Adarsh Ravishankar, Spandana Maddukuri, Jay Patel, Daisy Yan, Victoria P. Werth

4:00 PM

INCREASED PRO-INFLAMMATORY CONVENTIONAL DENDRITIC CELL SUBSETS IN CUTANEOUS LUPUS ERYTHEMATOSUS AND DERMATOMYOSITIS

Jay Patel#, Thomas Vazquez#, Victoria P. Werth

Short Talks – Presenters have 2 minutes for presentation

4:10 PM

USAGE OF IMMUNOSTIMULATORY HERBAL SUPPLEMENTS IN PATIENTS WITH AUTOIMMUNE SKIN DISEASES

Adarsh Ravishankar, Christina Bax, Daisy Yan, Josef S. Concha, Bridget E. Shields, Lisa Pappas-Taffer, Rui Feng, Joyce Okawa, Victoria P. Werth

4:12 PM

MRI IS NO MORE EXPENSIVE THAN AN EMG, AND MUCH LESS EXPENSIVE THAN MUSCLE BIOPSY IN PATIENTS WITH INFLAMMATORY MUSCLE DISEASE

Matthew F Helm, Galen T Foulke

4:14 PM

CHARACTERIZATION OF DERMATOMYOSITIS AND ASSOCIATED AUTOIMMUNE DISORDERS

Robert P Fort, Matthew F Helm, Steven Maczuga, Galen T Foulke

4:16 PM

INITIAL THERAPY FOR DERMATOMYOSITIS: MALIGNANCY RISK AND COST DIFFERENCE

Matthew F Helm, Melissa Butt, Steven Maczuga, Galen T Foulke

4:18 PM

INDIRECT COSTS, BURDEN AND WILLINGNESS TO PAY ASSOCIATED WITH CANCER SCREENING IN DERMATOMYOSITIS

Christopher Bazewicz, MD; Matthew Helm, MD; Melissa Butt, MPH; Cassidy Shumaker, MPH; Galen Foulke, MD

4:20 PM

A CASE OF TIF-g DERMATOMYOSITIS PRESENTING WITH PRURITUS AND “RED ON WHITE” PATCHES ON THE SCALP

Ellen B. Franciosi, BA, Alice Tan, BS, Laura Houk, MD, Mehdi Rashighi, MD



Oral Presentations - Lupus

Chair: Vicky Werth, MD

Presenters have 7 minutes for presentation and 3 minutes for questions

4:30 PM

CLINICAL AND HISTOPATHOLOGICAL ITEMS THAT DRIVE CLINICIAN CERTAINTY IN THE DIAGNOSIS DISCOID LUPUS ERYTHEMATOSUS

Scott A. Elman, MD; Cara Joyce, PhD; Victoria P. Werth, MD; Joseph F. Merola, MD, MMSc

4:40 PM

ELEVATED SERUM LEVELS OF CXCL10 CAN DISTINGUISH SYSTEMIC LUPUS ERYTHEMATOSUS FROM CUTANEOUS LUPUS ERYTHEMATOSUS PATIENTS

Jane L. Zhu, Jack C. O'Brien, Ramesh Saxena, Benjamin F. Chong

4:50 PM

USING THE CLASI DAMAGE SCORE TO CATEGORIZE AND IDENTIFY RISK FACTORS FOR WORSENING CUTANEOUS LUPUS DISEASE DAMAGE

Laila Abbas, BA, Karabi Nandy, PhD, Benjamin F Chong, MD, MSCS

5:00 PM

DISEASE ACTIVITY REMISSION AND RECURRENCE IN CUTANEOUS LUPUS ERYTHEMATOSUS

Stephanie Florez-Pollack, MD, Syed K. Rizvi, BS, Linda Hynan, PhD, Benjamin F. Chong, MD, MSCS

Short Talks – Presenters have 2 minutes for presentation

5:10 PM

DIFFERENCES IN DISCOID LUPUS DISTRIBUTION AND CHARACTERISTICS IN BLACK AND NON-BLACK PATIENTS

Adrienne Joseph, BS, Benjamin Chong, MD, MSCS

5:12 PM

DEVELOPMENT OF SYSTEMIC LUPUS IN PATIENTS WITH CUTANEOUS LUPUS USING THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS (SLICC) CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS

Samantha M Black, BS, Frances Walocko, MD, Xilong Li, PhD, Benjamin F. Chong, MD, MSCS

5:14 PM

QUALITY OF LIFE OF PATIENTS WITH FACIAL CUTANEOUS LUPUS ERYTHEMATOSUS

Josef Symon S. Concha, MD, Daisy Yan, BA, Adarsh Ravishankar, BS, Christina Bax, BA, Robert Borucki, MD, Rui Feng, PhD, and Victoria Werth, MD

5:16 PM

DIRECT IMMUNOFLUORESCENCE IN CONNECTIVE TISSUE DISEASE: A CROSS-SECTIONAL STUDY OF PAIRED H&E AND DIF SPECIMENS, WITH EMPHASIS ON LUPUS/DERMATOMYOSITIS

Heidi Vaughan, BSN, Rebecca Jacobson, BM, Jeffrey North, MD, M. Kari Connolly, MD, Anna Haemel, MD

5:18 PM

TRENDS IN INCIDENCE OF CUTANEOUS LUPUS ERYTHEMATOSUS FROM 1976 TO 2018: A POPULATION BASED STUDY

Mehmet Hocaoglu MD, Mark Davis MD, Shirley-Ann Osei-Onomah MPH, Jesse Y. Dabit MD, MSc, Rachel E. Giblon MS, T. J. O'Byrne, MAS, Cynthia S. Crowson PhD, Alí Duarte-García, MD, MSc

5:20 PM

MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN QUALITY OF LIFE FOR PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS

Motolani Ogunsanya B.Pharm, PhD; Justin M. McLawhorn, MD Talal Zahoor, MD Jarad Levin, MD Sung Kyung Cho BA Grant Barber BSc Benjamin Chong, MD, MSCS

5:22 PM

PRIMARY CUTANEOUS GAMMA-DELTA T-CELL LYMPHOMA DISGUISED AS LUPUS PANNICULITIS

Nicholas Leonard BS, Gregory Orłowski MD PhD, Eric Evan-Browning MD, Mehdi Rashighi MD

5:30 PM RDS Business meeting

6:00 PM Adjourn